Clinical trials: Antipsychotic
Cocaine-Related Disorders, Substance-Related Disorders
Quetiapine for Cocaine Use and Cravings
The purpose of this study was to collect pilot data on whether quetiapine may be effective in the reduction of cocaine use and cravings in cocaine dependent individuals.
- Trial name
- NCT00232336
- Testing
- quetiapine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Psychotic Disorders, Schizophrenia
Study of the Effect of Dosing on Clozapine Levels
The objectives of this 15-day study are: 1. To compare steady-state trough plasma concentrations of clozapine and its metabolite norclozapine when given once daily and twice daily (at the same total daily dose) 2.
- Trial name
- PK-CLZ (NCT02286206)
- Testing
- Clozapine
- Where
- Canada
- Sponsor
- University of British Columbia
Schizophrenia
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
Main objective: To assess the efficacy of two antidepressants of different pharmacological families: citalopram (Selective serotonin reuptake inhibitors, SSRI) and reboxetine (Norepinephrine Reuptake inhibitor, NRI) as adjunct…
- Trial name
- NCT01300364
- Testing
- Reboxetine, citalopram (SSRI)
- Where
- Spain
- Volunteers
- 249 people
- Sponsor
- Fundació Sant Joan de Déu
Antipsychotics and Neuroleptics Toxicity
Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
Atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia, akathisia, parkinsonism (rigidity and tremor), tardive dyskinesia…
- Trial name
- NCT06200584
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- Pakistan
- Volunteers
- 140 people
- Sponsor
- Dr Rabia Arshad
Schizophrenia
Oxytocin Add on Study for Stable Schizophrenic Patients
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with…
- Trial name
- Oxytocin (NCT00506909)
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- David Feifel
Depression, Catatonia
Survey on Pre-ECT Evaluation and ECT Application
The aim of this study is to identify specifics of pre-ECT assessments and ECT application in European psychiatric services. We will engage European centres that provide ECT for psychiatric patients and for psychiatric…
- Conditions
- Depression, Catatonia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT04335916
- Where
- Croatia
- Volunteers
- 30 people
- Sponsor
- Klinički Bolnički Centar Zagreb
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
The purpose of the study is to assess the safety and effectiveness of risperidone (an antipsychotic medication) in adolescents with schizophrenia over 6 months of treatment.
- Trial name
- NCT00246285
- Testing
- risperidone
- Volunteers
- 381 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia and Schizoaffective Disorder
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
- Trial name
- NCT00347425
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- 122 sites in United States, Argentina and 7 more
- Volunteers
- 286 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Psychoses
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
Prodrome based early intervention with an antipsychotic drug vs. benzodiazepine was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment.
- Trial name
- NCT00159133
- Testing
- antipsychotics vs. Lorazepam (Drugs)
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia
Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
- Trial name
- NCT00073320
- Testing
- Paliperidone Palmitate
- Volunteers
- 88 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intellectual Disability, Developmental Disability
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease.
- Conditions
- Intellectual Disability, Developmental Disability, Obesity
- Trial name
- METIDD (NCT05744479)
- Testing
- Metformin, Lifestyle Intervention
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute…
- Trial name
- NOVA2 (NCT07363577)
- Testing
- LB-102 (50 mg tablet), LB-102 (100 mg tablet)
- Where
- 13 sites in United States
- Volunteers
- 456 people
- Sponsor
- LB Pharmaceuticals Inc.
Stroke
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and…
- Trial name
- NCT04002700
- Testing
- Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
- Where
- United States
- Volunteers
- 1,234,412 people
- Sponsor
- Janssen Research & Development, LLC
Insulin Resistance, Body Composition
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
This project aims to a) evaluate the effects of haloperidol, olanzapine, and risperidone in combination with valproate on insulin secretion and insulin actions, b) evaluate medication effects on abdominal fat, total body fat and…
- Trial name
- DepIVGTT (NCT00552500)
- Testing
- Depakote (valproate)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
High Risk MC4R Genotype, Low Risk MC4R Genotype
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and adolescents aged 13-18 years old.
- Conditions
- High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
- Trial name
- NCT01844700
- Testing
- Ziprasidone, aripiprazole, quetiapine, or risperidone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwell Health
Bipolar Disorder, Manic Episode
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo in treating mania during 3 weeks of treatment in patients with Bipolar I Disorder who suffer from…
- Trial name
- NCT00249236
- Testing
- Risperidone, oral tablets
- Volunteers
- 291 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metabolic Syndrome X
Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone.
- Trial name
- NCT00956189
- Testing
- amisulpride, aripiprazole
- Where
- 3 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- National Taiwan University Hospital